Fosamax (Alendronate) Dosing for Adults Ages 50, 64

What Is the Correct Alendronate Dose for Adults Ages 50, 64?

The FDA approves two distinct oral tablet regimens for this age group, and the right one depends on whether the goal is treating established osteoporosis or preventing bone loss in someone who still has osteopenia. For treatment, the standard is 70 mg once weekly. For prevention, 35 mg once weekly is the approved option. Both are bioequivalent to their daily counterparts on a weekly-total-milligram basis, and the weekly tablet was developed specifically to improve adherence without sacrificing efficacy [1].

Adults in the 50, 64 age band occupy a clinically distinct window. Women in this group are often one to ten years past their final menstrual period, the phase during which trabecular bone loss accelerates fastest, sometimes reaching 2 to 3% per year in the spine [2]. Men in this range may be experiencing gradual testosterone decline, which correlates with measurable cortical bone thinning at the hip. At the same time, this group typically has fewer comorbidities than adults over 65, meaning fewer absolute contraindications and a longer projected treatment horizon. Getting the starting dose and the administration technique right at the outset is therefore especially consequential.

The prescribing clinician chooses between treatment-dose and prevention-dose based on DEXA results interpreted with T-score thresholds from the World Health Organization: a T-score at or below -2.5 defines osteoporosis and calls for the 70 mg weekly dose, while a T-score between -1.0 and -2.5 (osteopenia) may warrant the 35 mg weekly prevention dose, particularly when 10-year FRAX fracture probability is elevated [3].

FDA-Approved Dosing Regimens in Detail

Alendronate is available in four oral formulations relevant to this age group.

70 mg tablet, once weekly. This is the most commonly prescribed option for osteoporosis treatment in the 50, 64 group. It is taken on the same day each week, first thing in the morning, with at least 6, 8 ounces of plain water. No other food, beverage, or medication should be taken for at least 30 minutes afterward [4].

10 mg tablet, once daily. Bioequivalent to the weekly 70 mg regimen on a cumulative weekly-dose basis. Some clinicians prefer the daily option when they want stricter pharmacokinetic consistency, though trial data from the Fracture Intervention Trial (FIT) used a 5 mg/10 mg daily protocol rather than the weekly regimen because the weekly tablet was introduced after the trial was designed [5].

35 mg tablet, once weekly. Approved for prevention of osteoporosis in postmenopausal women. This dose is sometimes initiated when a 50, 64-year-old woman has newly entered menopause and her T-score has not yet crossed the osteoporosis threshold but her FRAX score or bone loss rate suggests she will cross it within 2 to 5 years.

5 mg tablet, once daily. The daily prevention-dose equivalent to 35 mg weekly. Less commonly used now that the weekly formulation is available and generically priced.

A 70 mg effervescent tablet dissolved in 4 ounces of plain water also exists for patients who have swallowing difficulty, though it is less often needed in the 50, 64 age group than in older cohorts [4].

The FIT Trial: The Fracture Evidence Behind These Doses

The Fracture Intervention Trial remains the foundational efficacy study for alendronate in postmenopausal women, and its findings directly justify the 10 mg daily (and by extension 70 mg weekly) dosing in the treatment-indication group [5].

FIT enrolled 2,027 women aged 55, 81 with low femoral neck bone density and at least one existing vertebral fracture. Participants received either alendronate (5 mg daily for two years, then 10 mg daily for one year) or placebo. Over 36 months, alendronate reduced the incidence of new morphometric vertebral fractures by 47% (8.0% placebo vs. 4.3% alendronate; P<0.001) [5]. Hip fracture risk fell by 51% in the alendronate group. Clinical vertebral fractures, which are the painful, symptomatic subset, were reduced by 55%.

A second FIT cohort (N=4,432 women without prevalent vertebral fracture) confirmed that alendronate significantly reduced vertebral fracture risk in women with femoral neck T-scores at or below -2.5, establishing that DEXA threshold as the treatment trigger still used in current guidelines [6].

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines specifically name alendronate as a first-line oral option for postmenopausal osteoporosis, citing its decade-long safety record and the FIT fracture data [7]. The AACE document states: "Alendronate, risedronate, and zoledronic acid are first-line options for most postmenopausal women with osteoporosis based on anti-fracture efficacy demonstrated in randomized controlled trials."

How to Take Alendronate Correctly: Administration Rules That Affect Dosing Outcomes

Taking the correct dose in the wrong way is functionally the same as underdosing. Alendronate's oral bioavailability is only 0.6 to 0.7% under ideal fasting conditions. Any calcium, magnesium, iron, or food in the stomach reduces absorption further, sometimes to near zero [4].

The rules are not suggestions.

Take the tablet immediately after getting out of bed, before eating, drinking anything except plain water, or taking any other medication. Use at least 6, 8 ounces (180 to 240 mL) of plain tap or bottled water. Do not use mineral water, coffee, juice, or any calcium-containing beverage. Swallow the tablet whole. Do not crush or chew it because direct mucosal contact can cause oropharyngeal ulceration. Remain upright (standing or sitting) for at least 30 minutes after swallowing, and do not lie down until after the first meal of the day. This upright positioning prevents esophageal reflux of the tablet, which is the primary mechanism behind esophageal ulceration, the most serious local adverse effect [4].

For the 50, 64 age group specifically, a common dosing error involves morning polypharmacy. Adults in this group frequently take thyroid hormone (levothyroxine), antihypertensives, or statins in the morning. Alendronate must be taken first, with only plain water, and all other morning medications are deferred by at least 30 minutes. Calcium supplements in particular should be separated by at least 30 minutes, though separating by 1 to 2 hours is a safer margin in practice [4].

Renal Dosing Considerations for Adults 50, 64

Kidney function does not typically become a limiting factor until later in life, but early chronic kidney disease (CKD stages 1, 2) can appear in the 50, 64 group, particularly in patients with long-standing hypertension, type 2 diabetes, or a history of NSAID use.

The FDA labeling for alendronate states that the drug is not recommended in patients with a creatinine clearance (CrCl) <35 mL/min [4]. Below that threshold, bisphosphonate accumulation in bone increases unpredictably and the risk of adynamic bone disease rises. Above that threshold, no dose reduction is required. The full 70 mg weekly treatment dose is used unchanged in patients with CrCl 35 to 60 mL/min (CKD stage 3a/3b), though some nephrologists prefer to monitor more frequently in that range [8].

Calculating CrCl using Cockcroft-Gault (rather than relying solely on eGFR) is relevant here because serum creatinine alone can underestimate renal impairment in lean or sarcopenic patients, and the 50, 64 age window is when muscle mass first begins to decline measurably in sedentary adults.

Drug Interactions Relevant to the 50, 64 Age Group

Polypharmacy intersects with alendronate in several specific ways that matter more in the 50, 64 group than in younger adults.

NSAIDs and aspirin. Concurrent NSAID use more than doubles the risk of upper GI events with bisphosphonates. A retrospective analysis of over 400,000 bisphosphonate users found that concomitant NSAID use was associated with a relative risk of 1.8 for upper GI hospitalization compared with bisphosphonate use alone [9]. Adults in this age group using NSAIDs for musculoskeletal pain should be counseled explicitly about this interaction. Switching to acetaminophen or a topical NSAID may reduce that risk.

Calcium and antacids. These directly chelate alendronate in the GI lumen and must be separated by at least 30 minutes, as noted above.

Corticosteroids. Systemic glucocorticoids accelerate bone loss by suppressing osteoblast activity and increasing urinary calcium excretion. Adults in the 50, 64 group on chronic prednisone doses of 5 mg/day or more for 3 or more months meet the American College of Rheumatology criteria for glucocorticoid-induced osteoporosis (GIOP) treatment, and alendronate 70 mg weekly is one of the first-line GIOP options [10].

Proton pump inhibitors (PPIs). PPIs do not significantly affect alendronate absorption, but they are frequently co-prescribed to reduce GI side effects. Co-prescription is reasonable in patients who have a documented history of peptic ulcer disease or GERD, though PPIs themselves carry a separate signal for reduced calcium absorption with long-term use.

Monitoring After Starting Alendronate at Ages 50, 64

Initiating alendronate in a 50, 64-year-old typically means a treatment horizon of at least 5 years, possibly longer. Monitoring should be structured accordingly.

DEXA scanning should be repeated at 1 to 2 years after initiating therapy to confirm a response (stable or increasing BMD). The minimum significant change on most DXA machines is approximately 3 to 4% at the lumbar spine. A patient who loses BMD despite adherent alendronate use should be evaluated for secondary causes of osteoporosis (hyperparathyroidism, celiac disease, vitamin D deficiency) before the dose is changed or a different agent is considered [7].

Bone turnover markers, specifically serum C-telopeptide (CTX) or urinary N-telopeptide (NTX), fall within 3 to 6 months of starting an effective bisphosphonate regimen. A CTX that remains in the upper normal range at 6 months may indicate poor adherence or absorption problems rather than drug failure.

25-hydroxyvitamin D should be measured at baseline. Alendronate cannot work in the presence of severe vitamin D deficiency because secondary hyperparathyroidism from low vitamin D accelerates bone resorption through a mechanism that bisphosphonates cannot fully counter. Most guidelines recommend maintaining serum 25(OH)D above 30 ng/mL (75 nmol/L) during bisphosphonate therapy [7].

Calcium intake should also be assessed. Adults aged 50, 64 require 1,000, 1 to 200 mg of elemental calcium daily from food and supplements combined. Deficient calcium intake reduces the drug's effective substrate.

Drug Holiday: When to Reassess After 3, 5 Years

The concept of a bisphosphonate drug holiday emerged from data showing that alendronate incorporates into bone mineral and continues to suppress bone turnover for years after stopping. The 10-year extension of the FLEX trial (Fracture Intervention Trial Long-term Extension, N=1,099) found that women who continued alendronate for 10 years had modestly lower vertebral fracture rates than women who stopped at 5 years, but hip BMD trajectories were similar between groups after the 5-year mark [11].

For adults aged 50, 64 who began alendronate at the start of this age window and have a T-score that has improved to above -2.5 at the hip, a 3-to-5-year drug holiday is a reasonable discussion point at the first reassessment. The holiday is not appropriate for patients who entered treatment with a T-score below -3.0, had a prior fragility fracture, or are on concurrent glucocorticoids [7].

A practical decision framework for the 50, 64 group:

• Start at 70 mg weekly if T-score is at or below -2.5 at hip or spine, or if FRAX 10-year major osteoporotic fracture probability exceeds 20%.
• Reassess at 3 to 5 years with repeat DEXA.
• Continue if T-score remains below -2.5, if a new fracture occurred on therapy, or if FRAX risk remains high.
• Consider a 2-to-3-year holiday if T-score has risen above -2.5 and the patient has no prior fragility fracture.
• Restart if T-score falls below -2.5 again on post-holiday monitoring or if a fracture occurs during the holiday.

Common Side Effects and How to Minimize Them in This Age Group

Upper GI symptoms are the most frequent reason adults in the 50, 64 group stop alendronate prematurely. Esophageal irritation, heartburn, and nausea occur in roughly 10 to 15% of patients in clinical series, though most cases are attributable to incorrect administration rather than an inherent drug toxicity [4].

Musculoskeletal pain (bone, joint, or muscle aches) has been reported in postmarketing surveillance and is mentioned in FDA labeling. Severe cases are rare. Onset can be days to months after starting therapy. Symptoms typically resolve after stopping alendronate, though resolution may take weeks.

Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) are rare but serious adverse effects more often discussed for bisphosphonates used in oncology doses (intravenous zoledronic acid monthly). With oral alendronate at osteoporosis doses, ONJ incidence is estimated at 1 in 10,000 to 1 in 100,000 patient-years, and AFF risk rises with longer cumulative duration, which is one reason the drug holiday discussion matters [12]. For a 50-year-old starting alendronate, the 5- to 10-year cumulative duration milestone arrives while the patient is still in relatively active life, making holiday planning part of the initial prescribing conversation.

Alendronate vs. Other Options for the 50, 64 Age Group

Alendronate is not the only bisphosphonate option, but it remains the most widely prescribed oral agent in this age group because of its generic availability, oral route, and the direct fracture-endpoint evidence from FIT.

Risedronate (Actonel, 35 mg weekly or 150 mg monthly) has a similar fracture reduction profile in the VERT trials and may cause fewer upper GI events in direct comparisons, making it a reasonable alternative for patients who develop GI intolerance on alendronate [13].

Zoledronic acid (Reclast, 5 mg IV once yearly) is preferred when adherence to weekly oral dosing is unlikely, when a patient cannot tolerate oral bisphosphonates due to GI disease, or when creatinine clearance falls below the oral bisphosphonate threshold. The HORIZON Key Fracture Trial (N=7,765) showed a 70% reduction in vertebral fractures and a 41% reduction in hip fractures over 3 years [14].

Denosumab (Prolia, 60 mg subcutaneously every 6 months) is increasingly used in the 50, 64 group when renal function limits bisphosphonate use or when the patient prefers a non-oral option. Denosumab does not accumulate in bone, which means that stopping it abruptly without a transition agent can cause rapid BMD loss and rebound fracture risk, a property that makes the treatment commitment more complex than with alendronate [7].

For men aged 50, 64 with osteoporosis (most commonly associated with hypogonadism, glucocorticoid use, or idiopathic causes), alendronate 10 mg daily or 70 mg weekly is FDA-approved and showed significant BMD gains in the male osteoporosis trial published in the New England Journal of Medicine: lumbar spine BMD increased by 7.1% vs. 1.8% placebo at 2 years (P<0.001) [15].

Starting Alendronate at Ages 50, 64: The Clinical Checklist

Before writing the prescription, the ordering clinician should confirm the following.

DEXA has been performed within the past 2 years and the T-score or FRAX probability meets the treatment threshold. Serum 25-hydroxyvitamin D has been checked and is above 20 ng/mL; if below 30 ng/mL, supplementation should be optimized before or at the time of bisphosphonate initiation. Creatinine clearance has been estimated and is at or above 35 mL/min. The patient has no active upper GI disease (active esophagitis, Barrett's esophagus with active inflammation, achalasia, or inability to sit upright for 30 minutes) that would make the oral route unsafe. A dental exam has been completed or is scheduled if the patient has active periodontal disease or requires major dental work, since initiating alendronate before completing invasive dental procedures reduces ONJ risk. Calcium and vitamin D intake have been assessed and supplemented to reach 1,000, 1 to 200 mg calcium and 600 to 800 IU vitamin D daily, the thresholds cited in the National Osteoporosis Foundation guidelines [16].

The patient has been counseled verbally and in writing on the 30-minute fasting rule, upright positioning, water volume, and the specific incompatibility of alendronate with calcium supplements taken simultaneously.

Written prescribing instructions should state the exact day of the week chosen for weekly dosing and should include a reminder that the dose is taken before any food, coffee, juice, or other medication. A 70 mg tablet taken on a full stomach with orange juice provides virtually none of the bone protection shown in FIT.